Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes

Journal of the American College of Cardiology

Volumn 56, Issue 1, 2010, Pages 77-85

  Weber, Michael A ^a   Bakris, George L ^b   Jamerson, Kenneth ^c   Weir, Matthew ^d   Kjeldsen, Sverre E ^e   Devereux, Richard B ^f   Velazquez, Eric J ^g   Dahlöf, Björn ^h   Kelly, Roxzana Y ⁱ   Hua, Tsushung A ⁱ   Hester, Allen ⁱ   Pitt, Bertram ^c  

^a SUNY Downstate Medical Center   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

amlodipine; coronary events; diabetes; hydrochlorothiazide; hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE PLUS BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; LOOP DIURETIC AGENT; SPIRONOLACTONE;

AGED; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE; COUGHING; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HEART ARREST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; STROKE;

AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; BLOOD PRESSURE; CORONARY DISEASE; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; RISK FACTORS;

EID: 77953646392     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.02.046     Document Type: Article

References (16)

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
2. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1054
3. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
4. Brenner B.M., Cooper M.E., De Zeeuw D., Keane W.F., Mitch W.E., and RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
5. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
6. Turnbull F., Neal B., Algert C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005) 1410-1419
7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991) 3255-3264
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
9. Dahlof B., Sever P.S., Poulter N.R., et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366 (2005) 895-906
10. Nissen S.E., Tuzcu E.M., Libby P., et al., CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (2004) 2217-2225
11. Luscher T.F., Wenzel R.R., Moreau P., and Takase J. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther 9 Suppl 3 (1995) 509-523
12. Neutel J.M., Smith D.H., and Weber M.A. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 17 (2004) 37-42
13. Jamerson K., Weber M.A., Bakris G.L., et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008) 2417-2428
14. Weber M.A., Bakris G.L., Dahlof B., et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press 16 (2007) 13-19
15. Haffner S. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. N Engl J Med 342 (2000) 1040-1042
16. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47 (2006) 352-358